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The structures and reactions of metal ions in proteins 
are of tremendous interest in bioinorganic chemistry, as 
is the potential for metals in creating novel medicines. 
New results combine these aspects in describing an 
unexpected mode for metal-mediated drug efficacy that 
relies on well-established principles of metalloprotein 
structure. 
molecule to the active site of a serine protease that does not 
ordinarily contain a metal ion. Involvement of the zinc ion 
greatly increases the affinity and selectivity of the inhibitor. 
Zinc biochemistry 
Address: Department of Chemistry, University of North Carolina at 
Chapel Hill, Chapel Hill, NC 27599-3290, USA. 
E-mail: holden@unc.edu 
Chemistry & Biology June 1998, 5:R125-R127 
http://biomednet.com/elecref/10745521005R0125 
Q Current Biology Ltd ISSN 1074-5521 
‘l’he discipline of bioinorganic chemistry aims to elucidate 
the mechanisms by which metal ions (usually transition 
metals) aid biological processes [1,2]. One third of all 
enL)mcs arc metalloenzymes in which metal ions play cat- 
alytic or structural roles. ‘I’he mechanisms by which metal- 
loenzymes activate small molecules such as _N2, CH,, O,, 
NO and HZ0 are under intense study [3], and the roles of 
metal ions in hydrolytic catalysis by proteins and b) 
riboqmcs are capti\,ating [4,.5]. Of equal importance is 
also the means b! \vhich the metal ions get into cells and 
subsequently into these metalloenzymes in the first place, 
and the field of metallorcgulation seeks to describe how 
gcncs arc turned on and off in response to changes in 
metal-ion conccntr;ltion [6.7]. 
Zinc is a star player in bioinorganic chemistry [l]. Many 
hydrolytic enzymes, such as carboxypeptidase and car- 
bonic anhydrase, utilize zinc in their active sites [12]. 
More recently, DNA-binding proteins that use zinc to 
organize structural elements, called zinc fingers, have 
been elucidated [ 131. Sufferers of the common cold turn to 
treatment with zinc lozenges that appear to shorten the 
duration and severity of cold symptoms under the right 
circumstances [14], possibly because of the involvement 
of zinc ions in the primary immune system [15]. Zinc is 
well suited to these roles because it is present at relatively 
abundant concentrations and binds to a number of donor 
atoms present in proteins. Bonding of transition metals to 
organic ligands is often described by the ‘hard-soft’ princi- 
ple where more polarizable lone pairs such as those in 
sulfur are considered ‘soft’ and less polarizable lone pairs 
such as those in oxygen are considered ‘hard’. In a 
hard-soft sense, zinc is a ‘borderline’ Lewis acid that 
binds to imidazole (histidine), carboxylate (aspartate and 
glutamate), thiolate (cysteine), and alkoxide (serine, thre- 
onine and tyrosine) donors (Figure 1) [IZ]. The d10 dica- 
tion is redox-inert, so hydrolytic enzymes can utilize zinc 
without heading down inadvertent redox pathways that 
would destroy the protein or substrate. Most bioavailable 
metal ions that bind to such a wide set of donors have 
some degree of redox activity 131. 
X number of pharmaceutical products and approaches 
utilize metal ions [Xl. The most well kno\vn example of 
these is the cancer chemotherapy agent cisplatin 
(c&l’t(NH,)Z(:lZ) that is widely used in treatment of 
ad\,anccd cancer and prorides an X0-90% success rate for 
testicular cancer patients [2]. Other metal drugs include 
gold compounds for treatment of arthritis, sodium nitro- 
prussidc for hypertension, technetium and rhenium 
radionuclides for diagnosis and therapy, and paramagnetic 
metal coniplcxcs for magnetic resonance contrast agents 
[9]. Recently, photodynamic therapy using metallopor- 
ph) rins and their deri\.ati\cs has attracted significant atten- 
tion [lO]. Yet, despite these success stories, it has been 
noted that the “applications of metals in medicine are far 
fe\\er than narranted by their potential” [a]. In a recent 
paper, Katz P~CC/. [l l] report a new mode for metals in medi- 
cine discovcrcd by traditional pharmaceutical techniques 
that center on protein crystallography and the conventional 
screening of organic small molecules. ‘I’he authors report 
that Ant ions can mediate the binding of a small organic 
Establishing the coordination environments that metal ions 
adopt in proteins is a major goal in bioinorganic chemistry 
[lb]. Because of the affinity of zinc for a wide range of 
donors, there are many different ligand sets in zinc proteins. 
Interested readers are referred to a recent comprehensive 
review [la], but some prominent examples of zinc proteins 
are shown in Figure 1. The zinc finger proteins exhibit a 
very soft environment consisting of two cysteine residues 
and two histidine residues in a tetrahedral array. This coor- 
dination environment has a high specificity for zinc because 
the soft thiolate ligands do not bind hard metal ions well. 
‘I’he zinc ion in carboxypeptidase A is coordinated to two 
histidine residues and a glutamate, leaving an open site in 
the tetrahedral array for a catalytically important water mol- 
ecule. Similarly, the active site of the enzyme carbonic 
anhydrase comprises a zinc ion situated on top of three his- 
tidinc residues with a water ligand available for catalysis. 
The enzyme astacin contains a five-coordinate zinc ion with 
three histidine residues, tyrosine, and a coordinated water 
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Figure 1 
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molecule. In just the four examples shown, zinc is found 
with thiolate, carboxylate, imidazole and alkoxide ligation, 
so zinc provides the unique combination of versatile coordi- 
nation with a failure to undergo redox chemistry. 
A new role 
Now, Katz eta/. [l 11 describe a new role for zinc in mediat- 
ing the binding of small molecule inhibitors to enzyme 
active sites. The authors have targeted serine proteases, a 
therapeutically interesting family of targets, with small 
molecule inhibitors based on bis(benzimidazoles), such as 
BABIM. These small molecule inhibitors bind to serine 
proteases with high affinity, giving values of K, as low as 
6 &I [ll]. IJpon careful examination of the X-ray crystal 
structures of the enzyme-inhibitor complexes, a novel 
mode of enzyme inhibition is found in which the enzyme 
and inhibitor have recruited an exogenous zinc ion to 
bridge the inhibitor and active-site residues. The enzvmc 
activity of serine proteases is based on a ‘catalytic triad’ of 
active-site residues that includes a serine residue (Ser195) 
and a histidine residue (His57), that must be hydrogen 
bonded to each other for the enzyme to function [17]. 
Figure 2 
Naturally occurring coordination environments 
for zinc. Four representative proteins with 
coordinates taken from the Brookhaven Data 
Bank. Structures of the zinc centers in (a) the 
zinc finger protein Zif268 from accession 
code 1 AAY [251, (b) carboxypeptidase A with 
a coordinated water molecule from 2CTB 
1261, (c) the sulfate complex of carbonic 
anhydrase from 1 CAI [27] and (d) astacin 
from 1 AST [28]. 
Binding of a zinc ion breaks the Ser-His hydrogen bond, 
and the resulting lone pairs coordinate the zinc ion 
(Figure 2). The other two coordination sites on zinc are 
filled by the two imidazole nitrogen atoms of the inhibitor, 
creating an environment that approximates coordination by 
three histidine residues and a (presumably deprotonated) 
serine residue. ‘l-his environment is very similar to that of 
carbonic anhydrase in which the zinc ion is coordinated by 
three imidazoles and a hydroxide ion [4,12]. 
Experiments with and without an exogenous EDTA chcla- 
tor show that the binding of the zinc ion enhances the 
affinity of the drug molecules by as much as 17,000-fold 
[ll]. Even more exciting, however, is the observation that 
the selectivity of the drug is enhanced. For example, one 
of the drugs showed a preference for thrombin over 
tryptase and trypsin that was enhanced by a factor of 4,800 
w:hen zinc was present, even though all three of these 
enzymes contain the catalytic Ser195 and His57 residues 
needed to coordinate the zinc ion. The selectivity must be 
a result of the geometry of the active-site pocket in the dis- 
torted protein, which must change conformation to bind 
His57 
I 
His57 
(-? ’ NH 
Scheme showing the capture of the catalytic 
residues of chymotrypsin by zinc ion and 
BABIM. Structure reproduced with 
permission from [l 11. 
the metal ion. The ternary complex must then be able to 
accommodate the tetrahedrally coordinated zinc ion and 
the accompanying drug molecule. This interaction requires 
much more specificity than binding the drug in the 
absence of zinc, because the organic l&and alone is flexible 
at the methylene carbon that joins the two imidazole rings. 
Katz d al. [ll] have identified a loop in thrombin that 
exhibits potential contactswith the metal-bound drug, pro- 
viding a conceptual framework for engineering selectivity 
for or against thrombin. 
Prospects 
AS Katz et nl. [I 1) note, these results suggest a large 
number of ne\v metal-protein-drug ternary complexes 
that are physiologically significant. There are many other 
enzymes that have nucleophilic groups in the active site 
that can coordinate metal ions, so extension of these con- 
ccpts to other protein-drug pairs and other metal ions is 
straightforward. (:ombinatorial methods of drug screening 
in combination with regulation of metal-ion concentra- 
tions \vill no doubt lead to many new ‘metalloproteins’ 
that consist of a metal ion bridging an active-site residues 
and a chelating drug. Of relevance here are recent studies 
showing that cobalt complexes target active-site residues 
and inhibit certain enzymes selectively [18]. 
Furthermore. although zinc is attractive because of its 
abundance, redox-inertness, and wide repertoire of coordi- 
nated ligands, sequestration of other metal ions by special 
protein-drug complexes is a further possibility. ‘I’herc 
have been significant efforts aimed at engineering metal 
sites into proteins using amino acid ligands resulting in 
new metal-ion-binding sites created by mutagenesis in 
proteins that do not bind metal ions [19], in synthetic pro- 
teins that bind metal ions [ZO] and in changes in metal-ion 
specificity in proteins that ordinarily bind a metal ion but 
now exhibit different preferences [Zl]. The concept of 
Katz YOU/. [ 1 I] in using the metal ion to promote selectivity 
bctueen the protein and drug might be reversed so that 
the protein-drug combination is specific for a certain metal 
ion. Such specificit) might bc desirable under conditions 
where binding a given metal ion is important, for example 
in sensing or in following metal-ion homeostasis [ZZ]. 
All these new applications \vill rely on continued advances 
in bioinorganic methods. Characterization of the structures 
of metal-ion-binding sites by X-ray crystallography and 
spectroscopic methods will expedite the discovery of neM 
physiologically relevant metal-protein complexes. Com- 
putational methods and algorithms for predicting the 
structures of metal ions in protein and chelate environ- 
ments [23,24] will now be of increased importance both 
for solving the structures of experimentally derived metal- 
loprotcins and for designing new metal-binding drugs that 
ha1.c high specificities and potencies. Bioinorganic chem- 
istr>- has been called ‘a maturing frontier’ [2] - probabl! 
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mature enough to shepherd the forthcoming barrage of 
new metal-drug-protein complexes towards realizing 
their full potential. 
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